Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

Chen Hsiung Yeh, Richard Tseng, Zhong Zhang, Jorge Cortes, Susan O'Brien, Francis Giles, Alison Hannah, Zeev Estrov, Michael Keating, Hagop Kantarjian, Maher Albitar

Research output: Contribution to journalArticle

Abstract

We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n = 93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n = 46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n = 95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P < 0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.

Original languageEnglish (US)
Pages (from-to)212-217
Number of pages6
JournalLeukemia Research
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

HSP70 Heat-Shock Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Disease Progression
Blood Proteins
Healthy Volunteers
Survival

Keywords

  • Chronic myeloid leukemia
  • Circulating heat shock protein
  • Imatinib resistance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. / Yeh, Chen Hsiung; Tseng, Richard; Zhang, Zhong; Cortes, Jorge; O'Brien, Susan; Giles, Francis; Hannah, Alison; Estrov, Zeev; Keating, Michael; Kantarjian, Hagop; Albitar, Maher.

In: Leukemia Research, Vol. 33, No. 2, 01.02.2009, p. 212-217.

Research output: Contribution to journalArticle

Yeh, CH, Tseng, R, Zhang, Z, Cortes, J, O'Brien, S, Giles, F, Hannah, A, Estrov, Z, Keating, M, Kantarjian, H & Albitar, M 2009, 'Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia', Leukemia Research, vol. 33, no. 2, pp. 212-217. https://doi.org/10.1016/j.leukres.2008.07.012
Yeh, Chen Hsiung ; Tseng, Richard ; Zhang, Zhong ; Cortes, Jorge ; O'Brien, Susan ; Giles, Francis ; Hannah, Alison ; Estrov, Zeev ; Keating, Michael ; Kantarjian, Hagop ; Albitar, Maher. / Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. In: Leukemia Research. 2009 ; Vol. 33, No. 2. pp. 212-217.
@article{21ee3fb20ffd4edd9cd491ea6d42f83d,
title = "Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia",
abstract = "We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n = 93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n = 46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n = 95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P < 0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.",
keywords = "Chronic myeloid leukemia, Circulating heat shock protein, Imatinib resistance",
author = "Yeh, {Chen Hsiung} and Richard Tseng and Zhong Zhang and Jorge Cortes and Susan O'Brien and Francis Giles and Alison Hannah and Zeev Estrov and Michael Keating and Hagop Kantarjian and Maher Albitar",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2008.07.012",
language = "English (US)",
volume = "33",
pages = "212--217",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

AU - Yeh, Chen Hsiung

AU - Tseng, Richard

AU - Zhang, Zhong

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Giles, Francis

AU - Hannah, Alison

AU - Estrov, Zeev

AU - Keating, Michael

AU - Kantarjian, Hagop

AU - Albitar, Maher

PY - 2009/2/1

Y1 - 2009/2/1

N2 - We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n = 93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n = 46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n = 95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P < 0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.

AB - We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n = 93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n = 46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n = 95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P < 0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.

KW - Chronic myeloid leukemia

KW - Circulating heat shock protein

KW - Imatinib resistance

UR - http://www.scopus.com/inward/record.url?scp=57049115429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049115429&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.07.012

DO - 10.1016/j.leukres.2008.07.012

M3 - Article

C2 - 18715642

AN - SCOPUS:57049115429

VL - 33

SP - 212

EP - 217

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -